GoodRx stock soars after CEO hints at potential TrumpRx partnership
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Morgan Stanley Reiterates Equalweight Rating on GoodRx Holdings Inc. (GDRX) Amid Speculation of TrumpRx
October 2, 2025 4:33 AM EDTMorgan Stanley analyst Craig Hettenbach reiterated an Equalweight rating and $5.00 price target on GoodRx Holdings Inc. (NASDAQ: GDRX)
The analyst comments "GDRX traded materially higher today (+19% vs. Russell 2000 +0.2%) on heavy volume (22mn shares or ~10x daily average) following news that the company could potentially partner with TrumpRx. This was discussed during an interview CEO Wendy Barnes had on Fox Business (article). Separately, we view news of an expansion with Kroger (covered by Simeon Gutman) as potentially the more meaningful... More
